Biotech Job Trends: Week Ending April 27, 2026

Welcome back to Biotech Job Trends, Company Canary's weekly snapshot of hiring activity across the biotech and biopharma companies our users follow. This was a big expansion week for coverage — nineteen new companies entered the tracker, more than double last week — and the composition of those additions tells a clear story about where the market's attention is concentrating right now.

A reminder on scope: the companies below reflect what Company Canary users have asked us to track, not a full biotech index. Coverage is broadening fast, but for now, treat this as a directional signal rather than a representative survey of the whole industry. We've also excluded a handful of very large employers (Sanofi, Pfizer, Eli Lilly, Amgen, AstraZeneca) along with two non-biotech trackers (Doximity, Zanskar) so the view isn't dominated by a few mega-cap posting volumes.

As of Monday, April 27, 2026:

Net change vs. last week: +223 active jobs and +19 companies. Most of that company-count growth came from one specific category, which is the storyline of this week's post.

Nineteen new companies entered the tracker over the past seven days. Rather than list all of them as one block, it's worth grouping by theme — because the composition is the story.

AI-first drug discovery & longevity (8 companies, 78 active jobs)

This is the headline cluster. Combined with Isomorphic Labs, Iambic Therapeutics, and Formation Bio (added last week), Company Canary now tracks roughly a dozen of the most-watched AI-bio platforms on the market.

• Generate Biomedicines — 19 active jobs. Flagship Pioneering's generative-biology platform for protein therapeutics, Somerville MA.
• insitro — 14 active jobs. Daphne Koller's ML-driven drug discovery company, South San Francisco.
• Genesis Molecular AI — 13 active jobs. Foundation models for chemistry and drug design.
• NewLimit — 13 active jobs. Brian Armstrong–backed longevity company developing epigenetic reprogramming therapies, SF Bay Area.
• Retro Biosciences — 7 active jobs. Sam Altman–backed longevity research lab targeting a 10-year extension to healthy lifespan, SF Bay Area.
• Valo Health — 6 active jobs. Human-data-driven discovery platform, Boston.
• Insilico Medicine — 5 active jobs. End-to-end generative AI drug discovery, with assets already in clinical development.
• Absci — 1 active job. Generative AI for antibody design, Vancouver WA.

Cell & gene therapy depth (4 companies, 51 active jobs)

• Iovance Biotherapeutics — 27 active jobs. TIL (tumor-infiltrating lymphocyte) therapy, recently commercial in melanoma.
• Prime Medicine — 14 active jobs. Next-generation prime editing — a more precise successor to base editing.
• Lyell Immunopharma — 7 active jobs. Engineered T-cell therapies for solid tumors, SF Bay Area.
• Caribou Biosciences — 3 active jobs. CRISPR-based allogeneic cell therapies, Berkeley.

Obesity & metabolic (3 companies, 27 active jobs)

Combined with Kailera from last week, the GLP-1 / obesity landscape is now well-represented in the tracker.

• Zealand Pharma — 14 active jobs. Peptide-based metabolic therapeutics, Copenhagen.
• Viking Therapeutics — 7 active jobs. Dual GLP-1/GIP agonist in late-stage trials, San Diego.
• Altimmune — 6 active jobs. GLP-1/glucagon dual agonist for obesity and MASH.

Other notable platforms (4 companies, 119 active jobs)

• Structure Therapeutics — 43 active jobs. Structure-based drug design, oral small molecules across cardiometabolic and pulmonary, San Francisco. The single largest new entrant this week.
• Twist Bioscience — 29 active jobs. Synthetic biology and DNA synthesis at scale, South San Francisco.
• Kymera Therapeutics — 25 active jobs. Targeted protein degradation, Watertown MA.
• Altos Labs — 22 active jobs. Cellular reprogramming and longevity, with high-profile institutes in San Diego, the Bay Area, and Cambridge UK.

The combined picture: Company Canary's coverage of AI-first drug discovery, next-generation gene editing, and obesity/metabolic has all materially deepened in a single week.

674 new job postings appeared across all tracked companies this past week. Of those:

• 375 were posted at companies already in the tracker before April 20 — genuinely new roles at established employers.
• 299 came in with the 19 newly-added companies. These aren't truly "new this week" — most were posted earlier and only entered our database when the company was added — but they're new to our coverage.

Three roles worth a look

A few postings stood out as interesting reads on where specific companies are investing:

1. Isomorphic Labs — Head of Translational Sciences, Drug Design (Cambridge, MA). A translational sciences leadership hire at an AI-first drug discovery company is a strong signal: their pipeline is moving close enough to humans that translational rigor is now a first-class function, not just a downstream outsourced step. One of the more meaningful "Isomorphic is becoming a real drug company" data points so far.
2. Recursion Pharmaceuticals — Staff Engineer, AI Security and Product Security (Salt Lake City, UT). AI-specific security as a dedicated function at a drug discovery company is genuinely new. As models become core IP, the security surface that needs protecting changes shape — and roles like this are early evidence of the industry catching up.
3. Natera — Vice President, Laboratory Software Engineering (US Remote). Posting a fully-remote VP-level engineering role at this seniority is unusual in biotech. Diagnostics companies are increasingly software-engineering-led, and Natera is staffing accordingly.

Where the volume is coming from

A handful of existing companies did most of this week's hiring at established employers:

• Regeneron (78 new postings) — still the broadest hirer, up from 72 last week. The functional mix shifted: 28 of 78 are manufacturing or operations roles (External Manufacturing Specialists, Biotech Production Coordinators, GMP Compliance, Warehouse Associates). This is a more pronounced manufacturing tilt than last week, suggesting continued capacity build-out at Tarrytown, Sleepy Hollow, and Rensselaer.
• Natera (39 new postings) — three notable clusters: a wave of Oracle Fusion technical roles (Technical Lead, Product Manager – SCM, Technical Program Manager) suggesting an active ERP migration; an IVD product development cluster (two Staff Scientists, one Senior Scientist); and the AI Staff Software Engineer + VP Laboratory Software Engineering pair mentioned above.
• Exact Sciences (35 new postings) — broad expansion across the Cancerguard MCED franchise (HCP Marketing Manager, Health Systems Marketing Director, Screening Medical Communications Director) and precision oncology specialty sales. A "Lead Supplier Manager – Complex Biologics" hints at upstream sourcing buildout.
• Biogen (32 new postings) — continued tilt toward commercial execution, with a notable "Head of Advertising, Labeling, and Promotion" hire signaling investment in regulated promotional infrastructure.
• Revolution Medicines (31 new postings) — first full week in the tracker. Heavy in oncology clinical and discovery roles, plus an Executive Director, Head of Contracting — typically a pre-launch commercial readiness hire.
• Vertex Pharmaceuticals (28 new postings), Illumina (24), Legend Biotech (19), Moderna (19), Neurocrine Biosciences (15).

Seniority skew of this week's new roles

Across the 375 new postings at existing companies, the distribution is broadly similar to last week — IC-heavy, with a meaningful director layer:

Level	Share of new roles
Individual Contributor	28.0%
Manager	14.1%
Senior (IC)	12.8%
Director	12.0%
Principal / Staff / Lead	9.9%
Associate Director	6.7%
Other	5.3%
Senior Manager	3.7%
Intern / Trainee	3.5%
Senior Director	1.9%
Executive Director	1.6%
VP+	0.5%

About 51% of this week's new roles are IC through Senior IC / Principal — companies are adding execution capacity, not building leadership benches. This shape has now held for two consecutive weeks.

Zooming out from the week to the full set of 2,966 active postings:

Seniority

The current active pool is more senior-weighted than the weekly inflow:

• ~31% director-and-above (Associate Director through VP+)
• ~18% manager-level (Manager + Senior Manager)
• ~10% principal / staff / lead
• ~31% IC / senior IC
• ~4% intern or trainee roles

That deep director bench remains the most distinctive feature of biotech-biopharma hiring relative to other industries.

Geography

The geographic mix shifted noticeably this week as the new companies — disproportionately Bay Area–based — entered the tracker:

Region	This week	Last week
Boston / Cambridge MA	15.7%	15.0%
SF Bay Area	12.5%	9.6%
Remote	11.3%	11.4%
NY / NJ metro	9.7%	12.6%
San Diego CA	6.6%	7.4%
Europe / UK	4.8%	4.7%
Asia-Pacific	4.2%	4.1%
Madison WI	2.1%	2.0%
Research Triangle NC	1.6%	1.9%

The Bay Area gained nearly three full percentage points in a single week — driven by the AI-first cluster (insitro, NewLimit, Retro Biosciences, Lyell, Twist, Structure Therapeutics) all clustering in San Francisco and South San Francisco. NY/NJ dropped meaningfully because Regeneron's share of a larger denominator shrank, not because Regeneron slowed down. Boston/Cambridge is still the leading metro, but the gap to the Bay Area has narrowed.

Function

A rough functional bucketing of active postings (these are approximate — title parsing only goes so far):

Function	Share
Clinical & Medical	16.7%
Commercial & Marketing	14.2%
Manufacturing & Operations	12.0%
Data, IT & Digital	9.7%
Regulatory & Quality	8.4%
Research & Discovery	7.4%
Finance & Legal	3.5%
Engineering (other)	2.1%
People & Admin	1.4%
Project / Program Mgmt	1.0%
Other / uncategorized	23.6%

Data, IT & Digital climbed from 6.8% last week to 9.7% this week — the largest single-week shift of any function category. The new AI-first companies post a much higher share of software, ML, and computational roles than traditional biopharma, and those postings are now showing up in the denominator. Worth tracking whether that share holds, climbs, or reverts as coverage continues to broaden.

• All figures reflect the state of the Company Canary database as of Monday, April 27, 2026.
• The dataset excludes seven companies for this post: Sanofi, Pfizer, Eli Lilly, Amgen, AstraZeneca (whose posting volumes would dominate the numbers), and two non-biotech entries (Doximity, Zanskar).
• Coverage is driven by what Company Canary users choose to track. It is not a representative sample of the biotech industry as a whole, and it tilts toward publicly-traded companies and well-known private ones. New companies are added every week, so the denominator will keep growing.
• A caveat specific to this week: when a new company is added, all of its currently-open roles enter the database simultaneously and get a first_seen_at timestamp from that moment. The 299 "new at new companies" jobs are therefore not all freshly-posted — they're new to our coverage, which is a slightly different concept than a fresh week's hiring activity. The 375 "new at existing companies" number is the cleaner read on real weekly hiring momentum.
• Seniority and function classifications are derived from job titles using pattern matching, so they're directional rather than exact. Geography is normalized from raw location strings and rolled up into metros or regions.

See you next Monday.